Revelation Biosciences, Inc.
corporate_fare Company Profile
Revelation Biosciences, Inc. (NASDAQ:REVB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for REVB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for REVB spans 10-Q, 8-K, DEF 14A, PRE 14A.
Recent high-impact activity:
- Revelation Cuts Gemini Kidney-Injury Trial Budget to ~$7M From ~$60M
- Q3 Net Loss Widens to $3.3M as Cash Falls to $9.1M; Runway Into Q2 2027
- Revelation Biosciences Q3 2026: $9.1M Cash, Going Concern, Nasdaq MVLS Delisting Risk
- Revelation Biosciences Sets 1-for-7 Reverse Split Effective October 20
- Revelation Biosciences posts Q2 2026 loss, holds $11.5M cash runway through Q1 2027, and advances pivotal AKI trial
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 12,792 shares in REVB as of the October 30, 2026 settlement, a 93.7% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 5.4% of REVB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.